Dr. Hoenle AG (HNL) AI Stock Analysis

• Market Cap: €59.53M
• Dividend Yield: N/A
• Average Volume (3M): 7.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: -3.11%
• EPS Growth: 9.59%
• Country: DE
• Employees: 585
• Sector: Industrials
• Sector Strength: 83
• Industry: Electrical Equipment & Parts
• EPS (TTM): 0.03
• Shares Outstanding: 6,062,930
• 10 Day Avg. Volume: 1,309
• 30 Day Avg. Volume: 7,600
• PEG Ratio: -0.52
• Price to Book (P/B): 3.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -117.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €22.00
• Price Target Upside: 124.49% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 53 Neutral
• Price Target: €10.00 ▲(2.04%Upside)

The overall stock score of 53 reflects the significant financial performance challenges faced by Dr. Hoenle AG, which are the most impactful factors weighing on the score. The technical analysis provides some positive signals that partially offset the financial weaknesses. Valuation concerns remain due to negative earnings and lack of dividend yield.

Dr. Hoenle AG Business Overview & Revenue Model

Company Description

Dr. Hoenle AG is a leading provider in the field of industrial UV technology, offering a wide range of products and services across sectors such as adhesives, coatings, and environmental engineering. The company specializes in developing and manufacturing UV lamps, UV equipment, and UV systems, which are used in various applications including curing, drying, and disinfection processes. With a focus on innovation and quality, Dr. Hoenle AG serves industries such as printing, automotive, electronics, and medical technology.

How the Company Makes Money

Dr. Hoenle AG generates revenue primarily through the sale of its UV technology products and systems. The company's key revenue streams include the manufacturing and distribution of UV curing and drying systems, UV disinfection systems, and specialty adhesives. Additionally, Dr. Hoenle AG offers maintenance services and technical support for their products, enhancing customer satisfaction and creating a recurring income stream. The company also engages in strategic partnerships with other industrial firms to expand its market reach and leverage cross-industry innovations. By continuously investing in research and development, Dr. Hoenle AG ensures the competitiveness and advancement of its product offerings, contributing significantly to its revenue growth.

Dr. Hoenle AG Financial Statement Overview

Summary

Dr. Hoenle AG faces significant financial challenges, with declining revenues and profitability issues impacting overall performance. The balance sheet reveals a dependence on debt, while cash flows show some positive trends but remain volatile.

Income Statement

Dr. Hoenle AG's revenue has declined over recent periods, with a negative revenue growth rate from 2023 to 2024. The company has been consistently reporting net losses, reflected in a negative net profit margin and EBIT margin for the TTM. Both gross and EBITDA margins are under pressure, indicating profitability challenges.

Balance Sheet

The balance sheet shows a moderately high debt-to-equity ratio, indicating a reliance on debt financing. The return on equity is negative due to net losses, which poses a risk. However, the equity ratio remains relatively stable, suggesting a reasonable proportion of equity financing.

Cash Flow

The company has shown some improvement in free cash flow, moving from negative to positive territory. The operating cash flow to net income ratio is positive, indicating cash generation despite net losses. However, the free cash flow growth is inconsistent, highlighting volatility in cash management.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
96.35M	98.73M	106.34M	116.09M	115.17M	93.88M
	Gross Profit
57.62M	57.99M	53.35M	69.28M	69.34M	60.54M
	EBIT
-9.83M	-10.26M	-9.42M	5.84M	349.00K	8.10M
	EBITDA
3.58M	3.07M	779.00K	20.41M	14.02M	14.82M
	Net Income Common Stockholders
-12.96M	-13.28M	-11.01M	-13.36M	-4.82M	5.68M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.47M	7.51M	9.32M	7.13M	12.07M	34.17M
	Total Assets
153.47M	155.38M	176.16M	195.46M	202.91M	196.20M
	Total Debt
54.23M	53.24M	56.89M	59.53M	53.64M	46.41M
	Net Debt
46.77M	45.73M	47.57M	52.40M	41.57M	12.24M
	Total Liabilities
74.28M	75.70M	80.02M	88.22M	91.78M	79.51M
	Stockholders Equity
78.91M	79.42M	95.82M	106.88M	110.72M	116.34M
Cash Flow		Free Cash Flow
1.42M	3.44M	209.00K	-11.71M	-15.96M	-22.96M
	Operating Cash Flow
3.59M	5.53M	3.14M	-7.41M	1.13M	7.23M
	Investing Cash Flow
-2.04M	-2.37M	2.65M	-1.69M	-24.50M	-30.74M
	Financing Cash Flow
-2.64M	-4.90M	-3.42M	3.73M	1.25M	43.25M

Dr. Hoenle AG Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:HNL, the sentiment is Neutral. The current price of 9.8 is below the 20-day moving average (MA) of 10.05, above the 50-day MA of 9.45, and above the 200-day MA of 9.51, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 46.97 is Neutral, neither overbought nor oversold. The STOCH value of 7.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:HNL.

Dr. Hoenle AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
S188	71 Outperform	€35.29M	4.94	8.05%	3.26%	44.76%	47.20%
Sector *	66 Neutral	$4.46B	12.15	5.40%	4.71%	4.16%	-11.97%
HNL	53 Neutral	€59.53M	―	-14.99%	―	-3.11%	9.59%

Dr. Hoenle AG Corporate Events

Dr. Hönle AG Voting Rights Update: Stake Reduction

Dr. Hönle AG, based in Gilching, Germany, announced a change in voting rights, with FundPartner Solutions (Europe) S.A. reducing its stake from 3.19% to 2.99% of voting rights attached to shares. This adjustment reflects a disposal of shares impacting the company’s shareholding structure, potentially influencing its strategic decisions and shareholder dynamics.

Dr. Hönle AG Reports Decrease in Voting Rights

Dr. Hönle AG, based in Gilching, Germany, has announced a change in its voting rights structure. The company’s voting rights, held indirectly through shares, have decreased from 3.19% to 2.99%, as reported by Quaero Capital S.A. This reduction may influence the company’s governance and stakeholder dynamics.

Dr. Hönle AG Reports Change in Voting Rights

Dr. Hönle AG, a company based in Gilching, Germany, has announced a change in its voting rights, reflecting a decrease in the shareholding threshold. As of February 7, 2025, Quaero Capital Funds (Lux), based in Luxembourg, has reduced its voting rights in Dr. Hönle AG from 3.19% to 2.99%, which translates to 181,531 voting rights. This shift in shareholder voting rights indicates a strategic adjustment in ownership stakes for stakeholders involved.